Intravenous Immunoglobulin (IVIg)
- Proposed mechanism of action is antagonization of fas-fas ligand activity
- No controlled studies have been performed with current evidence conflicted on its efficacy
- A summary of current evidence has been produced by French et al
- Despite this the use of IVIg is considered as a ‘Red’ indication for short term use by the department of Health Guidelines - considered the highest priority because of a risk to life without treatment
Ciclosporin
- Proposed mechanism of action is suppressant of T-cell function reducing keratinocyte apoptosis
- Data is scarce and of poor quality limiting recommendations